BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 33085712)

  • 1. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
    PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
    Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
    [No Abstract]   [Full Text] [Related]  

  • 5. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
    Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
    Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasis-directed Therapy (SBRT) Guided by PET-CT
    Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
    Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival in patients with
    Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
    Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
    Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
    Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
    Guler OC; Engels B; Onal C; Everaert H; Van den Begin R; Gevaert T; de Ridder M
    Clin Transl Oncol; 2018 Apr; 20(4):484-490. PubMed ID: 28795303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiotherapy to oligoprogressive lesions detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
    Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
    Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
    Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic response after 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases prostate cancer.
    Gawish A; Abdullayev N; El-Arayedh S; Röllich B; Ochel HJ; Brunner TB
    Clin Transl Oncol; 2023 Apr; 25(4):987-994. PubMed ID: 36369631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lesion Dosimetry for [
    Grkovski M; O'Donoghue JA; Imber BS; Andl G; Tu C; Lafontaine D; Schwartz J; Thor M; Zelefsky MJ; Humm JL; Bodei L
    J Nucl Med; 2023 Nov; 64(11):1779-1787. PubMed ID: 37652541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
    Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
    Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.